Leroux-Roels, I., et al. Safety and Immunogenicity of an Adjuvanted Clostridioides difficile Vaccine Candidate in Healthy Adults: A Randomized Placebo-Controlled Phase 1 Study.
Leroux-Roels, I., et al. Safety and Immunogenicity of an Adjuvanted Clostridioides difficile Vaccine Candidate in Healthy Adults: A Randomized Placebo-Controlled Phase 1 ...
Read More
Ison, M.G., et al. Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial.
Ison, M.G., et al. Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over...
Read More
Venkatraman, N., et al. Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.
Venkatraman, N., et al. Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human...
Read More
Haine, V., et al. Safety of RTS,S/AS01E malaria vaccine up to 1 year after the third dose in Ghana, Kenya, and Malawi (EPI-MAL-003): a phase 4 cohort event monitoring study.
Haine, V., et al. Safety of RTS,S/AS01E malaria vaccine up to 1 year after the third dose in Ghana, Kenya, and Malawi (EPI-MAL-003): a phase 4 cohort event monitoring stu...
Read More
Venkatraman, N., et al. R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study.
The study evaluates the efficacy and safety of the R21 malaria vaccine candidate (Jenner Institute, University of Oxford) formulated with the Matrix-M adjuvant (Novavax) ...
Read More
Ramezani-Rad, .P, et al. The saponin monophosphoryl lipid A nanoparticle adjuvant induces dose-dependent HIV vaccine responses in non-human primates.
The use of an appropriate adjuvant is crucial for developing an effective HIV vaccine. This study investigates the efficacy of QS-21-based saponin/monophosphoryl lipid A ...
Read More
Zhu, Q., et al. Harnessing phytochemicals: Innovative strategies to enhance cancer immunotherapy.
The article explores the promising role of phytochemicals, particularly saponins like Quil A and its derivative QS-21 from Quillaja saponaria, in enhancing cancer immunot...
Read More
Gaspar, E.B., et al. Adjuvant-driven antibody response to use cows as biofactories of anti-SARS-CoV-2 neutralizing antibodies in colostrum.
Bovine colostrum has the potential to serve as a source of neutralizing antibodies for preventing viral infections due to the evolutionary homology between bovine and hum...
Read More